PAX3 and cancer: Additionally, other genetic variants frequently found in cancers were identified, including MYC or MYCN mutations (one amplification each, 5%), and disease-specific gene fusions, including PAX3-FOXO1 in alveolar RMS (two out of two patients, 100%) and EWSR-FLI1 fusions in EWS (two out of four patients, 50%) (Fig. 3g).